MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319829 | Name: Gisadenafil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gisadenafil, also known as UK 369003, is a PDE5 inhibitor under development for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.

Chemical Structure

Gisadenafil
Gisadenafil
CAS#334826-98-1 (free base)

Theoretical Analysis

MedKoo Cat#: 319829

Name: Gisadenafil

CAS#: 334826-98-1 (free base)

Chemical Formula: C23H33N7O5S

Exact Mass: 519.2264

Molecular Weight: 519.62

Elemental Analysis: C, 53.16; H, 6.40; N, 18.87; O, 15.39; S, 6.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
334826-98-1 (free base) 334827-98-4 (besylate)
Synonym
Gisadenafil; Gisadenafilo; UK 369003; UK369003; UK-369003; UK 369,003; UK369,003; UK-369,003;
IUPAC/Chemical Name
5-(2-ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)pyridin-3-yl)-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
InChi Key
YPFZMBHKIVDSNR-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H33N7O5S/c1-5-18-19-20(27-30(18)12-13-34-4)22(31)26-21(25-19)17-14-16(15-24-23(17)35-7-3)36(32,33)29-10-8-28(6-2)9-11-29/h14-15H,5-13H2,1-4H3,(H,25,26,31)
SMILES Code
O=C1C2=NN(CCOC)C(CC)=C2N=C(C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CN=C3OCC)N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 519.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rawson DJ, Ballard S, Barber C, Barker L, Beaumont K, Bunnage M, Cole S, Corless M, Denton S, Ellis D, Floc'h M, Foster L, Gosset J, Holmwood F, Lane C, Leahy D, Mathias J, Maw G, Million W, Poinsard C, Price J, Russel R, Street S, Watson L. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem. 2012 Jan 1;20(1):498-509. doi: 10.1016/j.bmc.2011.10.022. Epub 2011 Oct 24. PubMed PMID: 22100260. 2: Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol. 2011 Sep;60(3):527-35. doi: 10.1016/j.eururo.2011.05.054. Epub 2011 Jun 12. Review. PubMed PMID: 21684677. 3: Watson KJ, Davis J, Jones HM. Application of physiologically based pharmacokinetic modeling to understanding the clinical pharmacokinetics of UK-369,003. Drug Metab Dispos. 2011 Jul;39(7):1203-13. doi: 10.1124/dmd.111.038224. Epub 2011 Mar 30. PubMed PMID: 21451120. 4: Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 2010 Sep;106(5):674-80. doi: 10.1111/j.1464-410X.2010.09204.x. PubMed PMID: 20184577. 5: Giuliano FA, Lamb J, Crossland A, Haughie S, Ellis P, Tamimi NA. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int. 2010 Sep;106(5):666-73. doi: 10.1111/j.1464-410X.2010.09205.x. PubMed PMID: 20151971.